Insulet (NASDAQ:PODD) Given New $388.00 Price Target at The Goldman Sachs Group

Insulet (NASDAQ:PODD) had its price objective lifted by The Goldman Sachs Group from $375.00 to $388.00 in a report released on Friday morning,MarketScreener reports. They currently have a buy rating on the medical instruments supplier’s stock.

Other equities research analysts have also issued research reports about the stock. Sanford C. Bernstein raised their price target on shares of Insulet from $400.00 to $410.00 in a report on Friday. BTIG Research restated a “buy” rating and set a $370.00 price target on shares of Insulet in a research report on Thursday. JPMorgan Chase & Co. increased their price objective on Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Wolfe Research raised their price objective on Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Canaccord Genuity Group upped their target price on shares of Insulet from $399.00 to $428.00 and gave the stock a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and an average price target of $371.38.

Insulet Stock Performance

Insulet stock traded down $3.58 during mid-day trading on Friday, reaching $319.82. The company’s stock had a trading volume of 677,166 shares, compared to its average volume of 721,278. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet has a 12-month low of $230.05 and a 12-month high of $353.50. The company has a market capitalization of $22.51 billion, a P/E ratio of 97.21, a PEG ratio of 2.64 and a beta of 1.39. The firm’s fifty day moving average price is $325.06 and its two-hundred day moving average price is $309.86.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. During the same period in the prior year, the company posted $1.08 EPS. The business’s revenue for the quarter was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts predict that Insulet will post 3.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.39% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Norges Bank bought a new stake in shares of Insulet during the second quarter valued at approximately $324,689,000. Qube Research & Technologies Ltd bought a new position in Insulet in the 2nd quarter valued at approximately $131,439,000. American Century Companies Inc. boosted its stake in Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after purchasing an additional 297,734 shares during the last quarter. Nuveen LLC bought a new stake in shares of Insulet in the 1st quarter worth $74,163,000. Finally, Worldquant Millennium Advisors LLC bought a new stake in shares of Insulet in the 2nd quarter worth $80,082,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.